Clinical Trial Update: A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the safety of retreatment with rituximab in patients with lupus nephritis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Lupus Nephritis | Phase 3 | Status: WITHDRAWN